Results 1 to 10 of about 112,825,263 (146)

The Role of CLEC-2 and Its Ligands in Thromboinflammation [PDF]

open access: yesFrontiers in Immunology, 2021
C-type lectin-like receptor 2 (CLEC-2, also known as CLEC-1b) is expressed on platelets, Kupffer cells and other immune cells, and binds to various ligands including the mucin-like protein podoplanin (PDPN).
Danyang Meng, Beibei Liu
exaly   +7 more sources

Lymphatic Blood Filling in CLEC-2-Deficient Mouse Models [PDF]

open access: yesPlatelets, 2021
C-type lectin-like receptor 2 (CLEC-2) is considered as a potential drug target in settings of wound healing, inflammation, and infection. A potential barrier to this is evidence that CLEC-2 and its ligand podoplanin play a critical role in preventing ...
Babak Mehrara, Ying Di, Zoltan Nagy
exaly   +7 more sources

The Structure of CLEC-2: Mechanisms of Dimerization and Higher-Order Clustering

open access: yesPlatelets, 2021
The platelet C-type lectin-like receptor CLEC-2 drives inflammation-driven venous thrombosis in mouse models of thrombo-inflammatory disease with a minimal effect on hemostasis identifying it as a target for a new class of antiplatelet agent.
Ying Di   +2 more
exaly   +5 more sources

Molecular Analysis of the Interaction of the Snake Venom Rhodocytin With the Platelet Receptor CLEC-2

open access: yesToxins, 2011
The Malayan pit viper, Calloselasma rhodostoma, produces a potent venom toxin, rhodocytin (aggretin) which causes platelet aggregation. Rhodocytin is a ligand for the receptor CLEC-2 on the surface of platelets.
Chris A O'Callaghan, Aleksandra A Watson
exaly   +4 more sources

C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes

open access: yesScientific Reports, 2022
Podoplanin (PDPN) is intensely expressed on the podocyte membrane in an evolutionally conserved manner. CLEC-2, the endogenous ligand of PDPN, is highly expressed in platelets and also exists in a soluble form in plasma.
Keiko Tanaka   +6 more
doaj   +2 more sources

Overcoming Challenges in Developing Small Molecule Inhibitors for GPVI and CLEC-2

open access: yesPlatelets, 2021
GPVI and CLEC-2 have emerged as promising targets for long-term prevention of both arterial thrombosis and thrombo-inflammation with a decreased bleeding risk relative to current drugs.
Luis A Moran   +2 more
exaly   +2 more sources

AVALIAÇÃO DA EXPRESSÃO DE PODOPLANINA E CLEC-2 NA DOENÇA FALCIFORME

open access: yesHematology, Transfusion and Cell Therapy, 2023
A hipercoagulabilidade é uma característica importante da doença falciforme (DF), e sua fisiopatologia está relacionada à ativação concomitante da hemostasia e da imunidade inata, em um processo conhecido como imunotrombose.
IT Borb-Junior   +5 more
doaj   +1 more source

The Association Between Plasma C-Type Lectin Like Receptors 2 (CLEC-2) and STEMI and its Correlation With Clinicolaboratory Data

open access: yesEgyptian Journal of Critical Care Medicine, 2023
Objectives To assess the association between plasma C-type lectin-like receptor 2 (CLEC-2) and ST elevation myocardial infarction (STEMI) and its correlation with clinicolaboratory data.
Salwa Hassan Ahmed   +4 more
doaj   +1 more source

Divalent nanobodies to platelet CLEC-2 can serve as agonists or antagonists

open access: yesCommunications Biology, 2023
Fluorescence correlation spectroscopy on crosslinked nanobodies tested on C-type lectin-like receptor 2 (CLEC-2) show different outcomes for divalent and tetravalent nanobody ligands on CLEC-2 clustering, also dependent on CLEC-2 expression levels.
Joanne C. Clark   +16 more
doaj   +1 more source

Clustering extent‐dependent differential signaling by CLEC‐2 receptors in platelets

open access: yesResearch and Practice in Thrombosis and Haemostasis, 2022
Background C‐type lectin receptor family members play a role in many cells including platelets, where they are crucial in the separation of lymphatic and blood vessels during development.
Carol Dangelmaier   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy